Literature DB >> 34956924

Malignant Struma Ovarii with Concurrent Thyroid Cancer: Outcomes during and after Pregnancy.

Sara Donato1, Helder Simões1,2, Valeriano Leite1,2,3.   

Abstract

INTRODUCTION: Struma ovarii (SO) is a rare ovarian teratoma characterized by the presence of thyroid tissue in more than 50% of the tumor. Malignant transformation is rare and the most common associated malignancy is papillary thyroid carcinoma (PTC). Pregnancy may represent a stimulus to differentiated thyroid cancer (DTC) growth in patients with known structural or biochemical evidence of disease, but data about malignant SO evolution during pregnancy are rare. We present the first reported case of a pregnant patient with malignant SO and biochemical evidence of disease. CASE
PRESENTATION: A previously healthy 35-year-old female diagnosed with a suspicious left pelvic mass on routine ultrasound was submitted to laparoscopic oophorectomy which revealed a malignant SO with areas of PTC. A 15-mm thyroid nodule (Bethesda V in the fine-needle aspiration cytology) was detected by palpation and total thyroidectomy was performed. Histology revealed a 15 mm follicular variant of PTC (T1bNxMx). Subsequently, she received 100 mCi of radioactive iodine therapy (RAIT) with the whole-body scan showing only moderate neck uptake. Her suppressed thyroglobulin (Tg) before RAI was 1.1 ng/mL. She maintained biochemical evidence of disease, with serum Tg levels of 7.6 ng/mL. She got pregnant 14 months after RAIT, and during pregnancy, Tg increased to 21.5 ng/mL. After delivery, Tg decreased to 14 ng/mL but, 6 months later, rose again and reached 31.9 ng/mL on the last follow-up visit. TSH was always suppressed during follow-up. At the time of SO diagnosis, a chest computed tomography scan showed 4 bilateral lung micronodules in the upper lobes which were nonspecific, and 9 months after diagnosis, a pelvic MRI revealed a suspicious cystic nodule located on the oophorectomy bed. These lung and pelvic nodules remained stable during follow-up. Neck ultrasonography, abdominal MRI, and fluorodeoxyglucose-positron emission tomography showed no suspicious lesions. DISCUSSION/
CONCLUSION: As for DTC, pregnancy seems to represent a stimulus to malignant SO growth. This can be caused by the high levels of estrogen during pregnancy that may bind to receptors in malignant cells and/or by the high levels of hCG which is known to stimulate TSH receptors.
Copyright © 2021 by European Thyroid Association Published by S. Karger AG, Basel.

Entities:  

Keywords:  Pregnancy; Struma ovarii; Thyroid cancer

Year:  2021        PMID: 34956924      PMCID: PMC8647070          DOI: 10.1159/000512735

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  14 in total

Review 1.  Malignant struma ovarii harboring a unique NRAS mutation: case report and review of the literature.

Authors:  Carlo Gobitti; Alessandro Sindoni; Chiara Bampo; Tanja Baresic; Giorgio Giorda; Lara Alessandrini; Vincenzo Canzonieri; Giovanni Franchin; Eugenio Borsatti
Journal:  Hormones (Athens)       Date:  2017-07       Impact factor: 2.885

2.  Sincronous malignant struma ovarii and papillary thyroid carcinoma.

Authors:  Pablo Fernández Catalina; Antonia Rego Iraeta; Mónica Lorenzo Solar; Paula Sánchez Sobrino
Journal:  Endocrinol Nutr       Date:  2016-06-11

3.  Malignant struma ovarii: a population-level analysis of a large series of 68 patients.

Authors:  Paolo Goffredo; Anna Mary Sawka; John Pura; Mohamed Abdelgadir Adam; Sanziana Alina Roman; Julie Ann Sosa
Journal:  Thyroid       Date:  2014-12-05       Impact factor: 6.568

4.  2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.

Authors:  Erik K Alexander; Elizabeth N Pearce; Gregory A Brent; Rosalind S Brown; Herbert Chen; Chrysoula Dosiou; William A Grobman; Peter Laurberg; John H Lazarus; Susan J Mandel; Robin P Peeters; Scott Sullivan
Journal:  Thyroid       Date:  2017-03       Impact factor: 6.568

5.  Thyrostimulin, but not thyroid-stimulating hormone (TSH), acts as a paracrine regulator to activate the TSH receptor in mammalian ovary.

Authors:  Su-Chin Sun; Pei-Jen Hsu; Fang-Ju Wu; Sheng-Hsiang Li; Chung-Hao Lu; Ching-Wei Luo
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

6.  Synchronous and Metachronous Malignancies After Malignant Struma Ovarii in the SEER Database.

Authors:  Andrea Sisti; Juri Tassinari; Giuseppe Nisi; Luca Grimaldi; Giovanni Sisti; Mariarosaria DI Tommaso; Massimiliano Fambrini
Journal:  In Vivo       Date:  2016 09-10       Impact factor: 2.155

Review 7.  A special case of bilateral ovarian metastases in a woman with papillary carcinoma of the thyroid.

Authors:  S Brogioni; P Viacava; L Tomisti; E Martino; E Macchia
Journal:  Exp Clin Endocrinol Diabetes       Date:  2007-06       Impact factor: 2.949

8.  Treatment and follow-up of malignant struma ovarii: Regarding two cases.

Authors:  Aurore Oudoux; Eric Leblanc; Juliette Beaujot; Hélène Gauthier-Kolesnikov
Journal:  Gynecol Oncol Rep       Date:  2016-06-08

9.  Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy - Lessons for management.

Authors:  Corey J Lager; Ronald J Koenig; Richard W Lieberman; Anca M Avram
Journal:  Clin Diabetes Endocrinol       Date:  2018-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.